The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx).
 
Tanya Gupta
Consulting or Advisory Role - bioTheranostics; Gilead Sciences; Pfizer
 
Ryon P Graf
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Epic Sciences; Foundation Medicine
 
Alexa B. Schrock
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine; Roche
 
Russell Madison
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Celsius Therapeutics; Tango Therapeutics
Research Funding - Foundation Medicine
 
Mia Alyce Levy
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Royalties from GenomOncology for licensing of MyCancerGenome content
 
Julia Quintanilha
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - United States Patent: "Methods of identifying risk of bevacizumab-induced proteinuria and hypertension", Innocenti F., Quintanilha J., Lin D., Owzar K., Wang J. Filed on July 17, 2020, serial number 16/932002; United States Provisional Patent Application: "Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab induced hypertension", Innocenti F., Quintanilha J. Filed on April 1, 2021, serial number 63/169301
Travel, Accommodations, Expenses - Foundation Medicine